Victory Capital Management
STAB

Victory Capital Management’s Statera Biopharma, Inc. Common Stock STAB Stock Holding History

Victory Capital Management’s Portfolio STAB Stock Details STAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-1,410
Closed -$2K – 3522
2020
Q1 		$2K Buy
+1,410
New +$2.88K ﹤0.01% 3706
2019
Q4 		– Sell
-859
Closed -$1K – 3506
2019
Q3 		$1K Buy
+859
New +$1.16K ﹤0.01% 3740

Other funds holding STAB

Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BRWA
B. Riley Wealth Advisors Boca Raton, Florida $1.87B AUM 37.01% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Carson Wealth (CWM LLC)
Carson Wealth (CWM LLC) Omaha, Nebraska $38.1B AUM 19.66% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Victory Capital Management's STAB Position: Q2 2020 in Review

Victory Capital Management sold out of Statera Biopharma, Inc. Common Stock (STAB) in Q2 2020, closing a stake of 1,410 shares — an estimated $2K sold.

Victory Capital Management first reported a position in STAB in Q3 2019 and held it in 2 quarters. The position peaked at $2K in Q1 2020. 17 funds tracked by Wall St. Rank hold STAB as of Q2 2020.

  • Victory Capital Management reported no remaining Statera Biopharma, Inc. Common Stock position as of Q2 2020 after selling out during the quarter.
  • Victory Capital Management sold 1,410 Statera Biopharma, Inc. Common Stock shares in Q2 2020, an estimated $2K.
  • Victory Capital Management first reported a position in Statera Biopharma, Inc. Common Stock in Q3 2019 and held it in 2 quarters.
  • Victory Capital Management's Statera Biopharma, Inc. Common Stock position peaked at $2K in Q1 2020.
  • 17 funds tracked by Wall St. Rank held Statera Biopharma, Inc. Common Stock as of Q2 2020.

Based on Victory Capital Management's 13F filing for Q2 2020, filed 7 Aug 2020.